Telix and Cardinal Health Complete Global Clinical Supply Agreement for Actinium-225 for Targeted Alpha Therapy Pipeline Development
Telix today announces an agreement with Cardinal Health Nuclear & Precision Health Solutions (a subsidiary of Cardinal Health, Inc.) for the global clinical supply of actinium-225 (Ac-225), a therapeutic radioisotope that will be used in developing the Company’s targeted alpha therapy (TAT) pipeline.